NAG
ALNY icon

Northstar Advisory Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Northstar Advisory Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,635
Closed -$686K – 98
2021
Q3 		$686K Buy
+3,635
New +$682K 0.67% 29

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Northstar Advisory Group's ALNY Position: Q4 2021 in Review

Northstar Advisory Group sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2021, closing a stake of 3,635 shares — an estimated $686K sold.

Northstar Advisory Group first reported a position in ALNY in Q3 2021 and held it in 1 quarter. The position peaked at $686K in Q3 2021. 433 funds tracked by Wall St. Rank hold ALNY as of Q4 2021.

  • Northstar Advisory Group reported no remaining Alnylam Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Northstar Advisory Group sold 3,635 Alnylam Pharmaceuticals shares in Q4 2021, an estimated $686K.
  • Northstar Advisory Group first reported a position in Alnylam Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Northstar Advisory Group's Alnylam Pharmaceuticals position peaked at $686K in Q3 2021.
  • 433 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2021.

Based on Northstar Advisory Group's 13F filing for Q4 2021, filed 20 Jan 2022.